A co-culture model of lung cancer meningeal metastases and choroid plexus organoids and its construction method
By introducing a matrix gel-mixed suspension into mature choroidal organoids and solidifying it in situ, combined with staged co-culture, the problem of unstable spatial relationships in the co-culture of lung cancer meningeal metastases and choroidal organoids was solved, achieving stability and continuity in three-dimensional co-culture.
Patent Information
- Application Number
- CN202611223435.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-13
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to stably establish the spatial relationship between lung cancer meningeal metastasis patients' cells and mature three-dimensional choroid plexus tissue within the same culture entity, and to ensure that the liquid components in the patient's cerebrospinal fluid continuously participate in the co-culture process. This results in a lack of a defined local tissue binding state between cells and tissues, and the separation of liquid components from cellular components after cerebrospinal fluid treatment affects the microenvironment relationship.
Using mature choroid organoids as carriers, cerebrospinal fluid-derived cells were pretreated and mixed with matrix gel to form a cell-matrix mixed suspension. This suspension was then introduced into the surface parenchymal region of mature choroid organoids through micropores, causing the matrix gel to solidify in situ and form organoid complexes. Combined with staged co-culture of cerebrospinal fluid supernatant, stable co-culture of cerebrospinal fluid-derived cells and choroid organoids was achieved.
Stable three-dimensional co-culture of lung cancer meningeal metastatic cells and choroid plexus organoids was achieved, maintaining the interrelationship between cerebrospinal fluid-derived cells and mature choroid plexus tissue, ensuring the continuous participation of cerebrospinal fluid liquid phase components in the same culture environment, and maintaining the continuity and stability of the three-dimensional co-culture state.
Smart Images

Figure CN123107904A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of brain metastasis in vitro model construction technology, specifically relating to a co-culture model of lung cancer meningeal metastasis cells and choroid plexus organoids and its construction method. Background Technology
[0002] In vitro models of brain metastasis and choroid plexus-related structures mainly include two-dimensional Transwell barrier models, dynamic microfluidic / organ-on-a-chip models, and choroid plexus organoid models. Two-dimensional Transwell barrier models can simulate cell migration across barriers, but their tissue structures are relatively simplified. Dynamic microfluidic / organ-on-a-chip models can reconstruct choroid plexus-related barriers and fluid environments, but they typically rely on pre-defined channels and engineered tissue partitions. Choroid plexus organoid models can form relatively complete three-dimensional choroid plexus tissue and are currently mainly used for studies on cerebrospinal fluid secretion, barrier function, and drug permeability.
[0003] In brain metastasis research, existing technologies can also utilize choroid plexus-associated cells (CLA-Associated Cells), microfluidic channels, extracellular matrix, and fluid conditions to establish in vitro culture systems, placing tumor cells in a choroid plexus-associated culture environment. For cerebrospinal fluid samples from lung cancer patients with meningeal metastases, the cellular components in the cerebrospinal fluid typically need to be separated and processed before entering the culture system, and then co-cultured with the choroid plexus-associated culture subjects according to the specific structural conditions of the model.
[0004] However, in the above-mentioned culture methods, a stable direct spatial binding relationship is still lacking between tumor cells and mature three-dimensional choroid plexus entities; the liquid components in the patient's cerebrospinal fluid fail to enter the same culture system along with the choroid plexus tissue and tumor cells; and there is a lack of a seamless processing procedure between the patient's cerebrospinal fluid-derived cells from the sample separation state to the three-dimensional co-culture state. Therefore, when using samples from lung cancer patients with dural metastases, it remains difficult to establish a stable and continuous co-culture relationship between the three-dimensional choroid plexus tissue, patient-derived cells, and the cerebrospinal fluid microenvironment within the same culture entity. Summary of the Invention
[0005] This invention overcomes the shortcomings of the prior art and provides a co-culture model of lung cancer meningeal metastases and choroid plexus organoids and its construction method.
[0006] To achieve the above objectives, the technical solution adopted by this invention is as follows: a method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids, comprising the following steps:
[0007] S1: Directed construction of choroidal organoids from human pluripotent stem cells to form mature choroidal organoids;
[0008] S2: Component separation and cell pretreatment of sterile cerebrospinal fluid from patients with lung cancer meningeal metastasis to obtain cerebrospinal fluid supernatant and cerebrospinal fluid-derived cell suspension;
[0009] S3: Cell volume preparation and matrix gel compounding based on cerebrospinal fluid-derived cell suspension to form a cell-matrix mixed suspension;
[0010] S4: Local implantation of mature choroidal organoids is performed by introducing a cell matrix gel mixture suspension into the mature choroidal organoids and coagulating it in situ to form an organoid complex.
[0011] S5: Using cerebrospinal fluid supernatant, organoid complexes were co-cultured in stages to obtain a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
[0012] Preferably, micropores leading to the superficial solid region are formed on the surface of mature choroidal organoids. A liquid cell matrix gel suspension is introduced into the superficial solid region through the micropores, and the matrix gel is solidified in situ in the introduced region by heating, so that the cerebrospinal fluid-derived cells are fixed in the local tissue region of the mature choroidal organoid.
[0013] Preferably, 20,000 cerebrospinal fluid-derived cells are configured for each mature choroid plexus organoid; the matrix gel and co-culture basal medium are mixed at a volume ratio of 1:5 to form a diluted matrix gel, the cerebrospinal fluid-derived cells are resuspended in the diluted matrix gel, and the final mixing volume of the matrix gel suspension corresponding to each mature choroid plexus organoid is adjusted to 5-10 μL. The matrix gel dilution and cell recombining process is maintained at 2-8℃.
[0014] Preferably, a 30-32 G sterile fine needle is used to form the micropores from the outer surface of the mature choroid organoid towards the superficial parenchyma region, with an insertion depth of 100-300 μm; the cell matrix gel mixture suspension is introduced into the superficial parenchyma region through the micropores for 30-60 s, and after the introduction is completed, it is held for 1-3 min before the injection device is removed; then it is kept at 37℃ and 5% CO2 for 30 min to allow the matrix gel to solidify in situ.
[0015] Preferably, the cerebrospinal fluid supernatant and the cerebrospinal fluid-derived cells originate from the same sterile cerebrospinal fluid sample; after the organoid complex is formed, the cerebrospinal fluid supernatant is mixed with the co-culture basal medium at a volume ratio of 1:5 to form a co-culture medium containing the cerebrospinal fluid supernatant, and added to the culture system containing the organoid complex, so that the cerebrospinal fluid supernatant and the cerebrospinal fluid-derived cells fixed in the local tissue area of the mature choroid organoid are once again in the same culture environment.
[0016] Preferably, the co-culture medium containing cerebrospinal fluid supernatant is used for co-culture days 0-3, and the co-culture basal medium without cerebrospinal fluid supernatant is used after co-culture day 3. The organoid complex is first statically cultured at 37°C and 5% CO2 for 24 h, and then transferred to a track shaker and continuously cultured at 37°C and 5% CO2 at 70 rpm for a total co-culture time of 9 days.
[0017] Preferably, the sterile cerebrospinal fluid is centrifuged at 1000 r / min for 10 min at 4°C to obtain cerebrospinal fluid supernatant and cell pellet, respectively; the cell pellet is then subjected to red blood cell lysis, PBS washing, filtration through a 70 μm cell sieve, cell counting, and viability testing to obtain the cerebrospinal fluid-derived cell suspension.
[0018] Preferably, the choroid plexus organoid directed construction sequentially includes single-cell formation and aggregation culture, neural induction culture, matrix gel embedding and three-dimensional expansion culture, and choroid plexus differentiation and maturation culture. Specifically, initial organoids are formed on days 0-5, neural induction organoids are formed on days 5-7, expanded organoids are formed on days 7-10, choroid plexus differentiation culture is performed on days 10-15, and choroid plexus maturation culture is performed on days 15-30.
[0019] Preferably, choroid plexus differentiation culture is carried out on days 10-15 using choroid plexus differentiation medium containing 2-4 μM CHIR99021 and 15-25 ng / mL BMP4; after day 15, choroid plexus maturation medium without CHIR99021 and BMP4 is used, and the culture is carried out in an orbital shaker at 37℃ and 5% CO2 at 55-75 rpm, with fresh choroid plexus maturation medium replaced every 3-4 days, and the culture is continued until day 30.
[0020] Another technical solution provided by the present invention: a co-culture model of lung cancer meningeal metastatic cells and choroid plexus organoids, obtained by a co-culture method of lung cancer meningeal metastatic cells and choroid plexus organoids.
[0021] This invention addresses the shortcomings of the prior art and has the following beneficial effects:
[0022] This invention uses mature choroidal organoids as a three-dimensional tissue carrier. Cell components from cerebrospinal fluid (CSF) of lung cancer patients with meningeal metastases are pretreated, cell volume is adjusted, and matrix gel is mixed before being introduced into mature CSF. The local immobilization state is formed by in-situ coagulation of matrix gel. After the organoid complex is formed, the CSF supernatant obtained from the same CSF sample is added back to the culture system. A staged co-culture method combining static culture and track-shaking culture is adopted to form and maintain an interconnected three-dimensional co-culture state of CSF-derived cells, mature CSF organoids, and CSF liquid phase components in the same culture process.
[0023] This invention introduces a liquid cell-matrix suspension into the superficial solid region by creating micropores on the surface of mature choroid organoids. The matrix gel solidifies in situ within the introduced region, transforming cerebrospinal fluid-derived cells from an external organoid state to a fixed state within the local tissue region of the organoid. The micropore introduction establishes the initial spatial position of the cells relative to the three-dimensional choroid tissue, and the in-situ solidification of the matrix gel further restricts the spatial migration of cells during subsequent culture, thereby establishing a relatively stable direct local spatial relationship between the cerebrospinal fluid-derived cells and the mature choroid organoid.
[0024] This invention separates the components of the same sterile cerebrospinal fluid (CSF) sample, obtaining and preprocessing CSF-derived cells while independently retaining the CSF supernatant. After the CSF-derived cells have completed local implantation and formed organoid complexes, the CSF supernatant is then added to the culture system in a co-culture basal medium. Thus, the CSF liquid phase components act again on the CSF-derived cells already immobilized in the local tissue region of the mature choroid plexus organoid, ensuring that the patient-derived cells, CSF liquid phase components, and mature choroid plexus tissue are all in the same culture environment.
[0025] This invention sequentially links cerebrospinal fluid (CSF) component separation, cell pretreatment, cell mass configuration, matrix gel mixing, local organoid implantation, in-situ coagulation, CSF supernatant remixing, and staged co-culture. This allows CSF-derived cells to gradually transform from their isolated state in patient samples into a quantitatively configurable cell suspension, an importable cell-matrix mixed suspension, and a fixed state within a local tissue region of a mature choroid organoid. After this state is established, the cells continue to be subjected to CSF liquid phase components and staged culture conditions, thereby maintaining the continuity of the patient-derived cells in terms of object acceptance and state from sample processing to three-dimensional co-culture.
[0026] In this invention, cerebrospinal fluid (CSF) samples are separated into cellular and supernatant components, which serve as independent input sources for subsequent processing. The cellular components, after quantitative cell preparation and matrix gel compounding, form a cell-matrix mixture suitable for local organoid delivery. This mixture is introduced into the surface parenchymal region of mature choroid plexus organoids via micropores, and the CSF-derived cells are spatially immobilized and structurally stabilized within the organoid's local microenvironment through in-situ matrix gel coagulation. After establishing this local immobilization state, the CSF supernatant is returned to the co-culture system, and the organoid complex is continuously maintained using a phased culture approach combining static and dynamic culture on a track-shaking incubator. This process constructs a co-culture model of lung cancer meningeal metastases and choroid plexus organoids. Attached Figure Description
[0027] Other features, objects, and advantages of the invention will become more apparent from the following detailed description of non-limiting embodiments with reference to the accompanying drawings:
[0028] Figure 1 This is a perspective structural diagram of a preferred embodiment of the present invention;
[0029] Figure 2 This is an immunofluorescence image of AQP1 / MAP2 / DAPI in the choroid plexus organoids of Example 1;
[0030] Figure 3 This is an HE staining image of the choroid plexus organoids in Example 1;
[0031] Figure 4 This is a Western blot image of cerebrospinal fluid chaperone proteins in choroid organoids from Example 1;
[0032] Figure 5 This is an immunofluorescence image of CK7 / TTF1 / DAPI in the co-culture model of lung cancer meningeal metastases and choroid plexus organoids in Example 1;
[0033] Figure 6 The image shows the immunofluorescence pattern of CK7 / TTF1 / DAPI in the co-culture model formed by the drop-addition co-mixing method in Comparative Example 1.
[0034] Figure 7 This is an immunofluorescence image of CK7 / TTF1 / DAPI in the co-culture model formed by the chip co-matching method in Comparative Example 2. Detailed Implementation
[0035] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0036] Application Overview:
[0037] While existing in vitro models of choroid plexus can provide environments for cell migration across barriers, engineered fluid environments, or three-dimensional choroid plexus tissue environments, they still struggle to establish stable spatial relationships between patient-derived cells and mature three-dimensional choroid plexus tissue within the same culture entity when used with cerebrospinal fluid (CSF) samples from lung cancer patients with meningeal metastases. Furthermore, they fail to ensure the continuous participation of CSF liquid components in the co-culture process. Specifically, when cellular components from the patient's CSF enter the culture system only through suspension, surface contact, or pre-defined channel partitioning, a defined local tissue binding state is not formed between the cells and mature choroid organoids. Moreover, if the liquid components formed after CSF processing and the cellular components are processed separately, the shared microenvironmental relationship between the two types of components in the original CSF sample is disrupted. Therefore, simply using existing two-dimensional barriers, microarray partitioning, or individual choroid organoid culture pathways, or merely adjusting conventional conditions such as culture time and culture media, cannot directly alter the aforementioned spatial and component relationships.
[0038] Based on the aforementioned technical relationships, this invention does not simply change the culture medium or extend the co-culture time. Instead, it directly uses mature choroidal organoids as the three-dimensional tissue entity carrying cells derived from lung cancer meningeal metastases, and re-introduces the cellular and liquid components of the patient's cerebrospinal fluid into the same culture system after necessary treatment. The key change is to alter the initial spatial state of the cerebrospinal fluid-derived cells relative to the mature choroidal organoids, ensuring that the cells are no longer merely located in the external culture medium or on the organoid surface, but rather enter the local tissue region of the mature choroidal organoid before co-culture begins. Only by establishing this defined spatial relationship can the subsequent culture process maintain the co-culture relationship between the patient-derived cells and the three-dimensional choroidal tissue based on the established organoid complex.
[0039] Method implementation:
[0040] like Figure 1 As shown, a method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids includes the following steps:
[0041] S1: Directed construction of choroidal organoids from human pluripotent stem cells to form mature choroidal organoids;
[0042] S2: Component separation and cell pretreatment of sterile cerebrospinal fluid from patients with lung cancer meningeal metastasis to obtain cerebrospinal fluid supernatant and cerebrospinal fluid-derived cell suspension;
[0043] S3: Cell volume preparation and matrix gel compounding based on cerebrospinal fluid-derived cell suspension to form a cell-matrix mixed suspension;
[0044] S4: Local implantation of mature choroidal organoids is performed by introducing a cell matrix gel mixture suspension into the mature choroidal organoids and coagulating it in situ to form an organoid complex.
[0045] S5: Using cerebrospinal fluid supernatant, organoid complexes were co-cultured in stages to obtain a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
[0046] The following description, in conjunction with the specific implementation process of each step, further explains the method so that those skilled in the art can clearly understand the interrelationship of each step in implementation and the resulting technical results.
[0047] In step S1, the directed construction of choroid organoids includes single-cell formation and aggregation culture, neural induction culture, matrix gel embedding and three-dimensional expansion culture, and choroid plexus differentiation and maturation culture. Initial organoids are formed on days 0-5, neural induction organoids on days 5-7, expanded organoids on days 7-10, choroid plexus differentiation culture on days 10-15, and choroid plexus maturation culture on days 15-30.
[0048] Specifically, human pluripotent stem cells in a stable proliferative state are single-celled and aggregated for culture to form initial organoids.
[0049] Human pluripotent stem cells in a stable proliferative state are collected and digested with cell digestion solution to disperse adherent cells into a single-cell suspension. After digestion is terminated, the cells are collected, and the number of viable cells is determined by trypan blue exclusion method or equivalent cell counting method. The concentration of the single-cell suspension is adjusted according to the counting results.
[0050] 2000-4000 human pluripotent stem cells were seeded into single wells of a 96-well round-bottom ultra-low adsorption culture plate, with 150-200 μL of organoid formation medium added to each well. Aggregation culture was then carried out at 37°C and 5% CO2. The organoid formation medium was based on DMEM / F12, supplemented with 15%-20% KnockOut serum substitute, 2%-3% fetal bovine serum, 0.8%-1.2% GlutaMAX, 0.8%-1.2% MEM non-essential amino acids, 0.08-0.12 mM 2-mercaptoethanol, and 3-5 ng / mL basic fibroblast growth factor.
[0051] From day 0 to day 3 of culture, 5-20 μM of the ROCK inhibitor Y-27632 was added to the organoid formation medium. After day 3, the medium was replaced with organoid formation medium without Y-27632, and cultured until day 5. During culture, human pluripotent stem cells aggregated from dispersed single cells to form three-dimensional cell clusters. On day 5, three-dimensional cell clusters that were continuous, had smooth edges, and had no obvious disintegration areas were selected to obtain the initial organoids.
[0052] Furthermore, neural induction culture was performed on the initial organoids to form neurally induced organoids.
[0053] Initial organoids cultured to day 5 were retained in round-bottom ultra-low adsorption culture plates. The organoid formation medium was removed, and neural induction medium was added. The plates were then cultured at 37°C and 5% CO2 until day 7. The neural induction medium was based on DMEM / F12, with the addition of 0.8%-1.2% N2 additive, 0.8%-1.2% GlutaMAX, 0.8%-1.2% MEM non-essential amino acids, and 0.5-2 μg / mL heparin. No serum or serum substitutes were added.
[0054] During the culture process, the organoids maintain their complete three-dimensional morphology and form a continuous semi-transparent tissue region around them; neurally induced organoids are obtained by the 7th day of culture.
[0055] Furthermore, based on neurally induced organoids, matrix gel embedding and three-dimensional amplification culture were performed to form amplified organoids.
[0056] Take the neurally induced organoids cultured to day 7, remove the residual culture medium on the surface, and place a single neurally induced organoid in 20-30 μL of low-temperature liquid matrix gel, so that the matrix gel surrounds the organoid; place the embedded organoid at 37℃ for 15-30 min to allow the matrix gel to solidify and form a three-dimensional matrix environment.
[0057] After matrix gel solidification, the embedded neural-induced organoids were transferred to ultra-low adsorption culture plates and cultured in amplification medium until day 10. The amplification medium consisted of DMEM / F12 and Neurobasal medium at a 1:1 volume ratio as the basal culture medium, with the addition of 0.4%-0.6% N2 additive, 1.5%-2.5% vitamin A-free B27 additive, 2-3 μg / mL insulin, 40-60 μM 2-mercaptoethanol, 0.8%-1.2% GlutaMAX, 0.4%-0.6% MEM non-essential amino acids, and 0.8%-1.2% penicillin-streptomycin mixture.
[0058] By day 10 of culture, budding structures extending outwards form on the surface of the organoids, resulting in expanded organoids.
[0059] Furthermore, based on the amplified organoids, choroid plexus differentiation and maturation culture were carried out to form mature choroid plexus organoids.
[0060] On day 10, the amplification medium was replaced with choroid plexus differentiation medium. The choroid plexus differentiation medium was a basal culture medium composed of DMEM / F12 and Neurobasal medium at a 1:1 volume ratio, with the addition of 0.4%-0.6% N2 additive, 1.5%-2.5% vitamin A-containing B27 additive, 2-3 μg / mL insulin, 40-60 μM 2-mercaptoethanol, 0.8%-1.2% GlutaMAX, 0.4%-0.6% MEM non-essential amino acids, 0.8%-1.2% penicillin-streptomycin mixture, 2-4 μM CHIR99021, and 15-25 ng / mL BMP4, wherein CHIR99021 was preferably 3 μM and BMP4 was preferably 20 ng / mL.
[0061] During the 10th to 15th day of culture, choroid plexus differentiation medium was used, and fresh choroid plexus differentiation medium was replaced on the 3rd day after entering the choroid plexus differentiation culture to transform the expanded organoids into choroid plexus tissue state.
[0062] On day 15, the choroid plexus differentiation medium was replaced with choroid plexus maturation medium. The maturation medium used the same basal medium and nutrient supplements as the differentiation medium, but without CHIR99021 and BMP4. From day 15 to 30, choroid plexus maturation was carried out at 37°C and 5% CO2, with a rocker rotation speed of 55-75 rpm. The medium was replaced with fresh maturation medium every 3-4 days.
[0063] By day 30 of culture, the organoids formed dense tissue regions and peripheral sac-like structures, yielding mature choroid plexus organoids, which were then used as three-dimensional tissue objects for local S4 implantation.
[0064] In step S2, the separation of cerebrospinal fluid components and cell pretreatment includes low-temperature centrifugation and cell pellet pretreatment. Sterile cerebrospinal fluid is centrifuged at low temperature to form cerebrospinal fluid supernatant and cell pellet. The cerebrospinal fluid supernatant is stored independently. The cell pellet is subjected to erythrocyte lysis, washing, filtration, cell counting, and viability testing to form a cerebrospinal fluid-derived cell suspension.
[0065] Specifically, sterile cerebrospinal fluid from lung cancer patients with meningeal metastases was separated by low-temperature centrifugation to obtain cerebrospinal fluid supernatant and cell sediment.
[0066] The collected sterile cerebrospinal fluid was transferred to a sterile centrifuge tube and centrifuged at 1000 r / min for 10 min at 4°C to allow the cellular components in the cerebrospinal fluid to settle and form a cell precipitate. After centrifugation, the supernatant was aspirated without disturbing the cell precipitate and collected separately as the cerebrospinal fluid supernatant, while the cell precipitate at the bottom of the tube was retained.
[0067] Cerebrospinal fluid supernatant should be stored for a short period at 2-8°C. If it cannot be used for co-culture within 24 hours, it should be aliquoted according to the single-use volume and stored at -80°C. Before use, it should be thawed slowly at 2-8°C, and repeated freeze-thaw cycles should be avoided. The cerebrospinal fluid supernatant, as a liquid phase component of the same cerebrospinal fluid sample, should be reintroduced into the culture system in S5.
[0068] Furthermore, cell pretreatment is performed based on cell precipitation to form a cerebrospinal fluid-derived cell suspension.
[0069] Add 3-5 times the volume of red blood cell lysis buffer to the cell pellet, mix gently, and incubate at 4°C for 2-3 min. After the set lysis time is reached, add PBS to terminate and dilute the red blood cell lysis system. Centrifuge at 300-500×g for 5-10 min, discard the supernatant and retain the cell pellet.
[0070] The cell pellet was resuspended in PBS and washed once more. The washed cell pellet was then resuspended in PBS to form a cell suspension. The cell suspension was passed through a 70 μm cell sieve to remove larger aggregates that could not pass through the sieve pores, and the filtrate was collected.
[0071] Cells in the filtrate were counted and their viability was tested. The concentration of the cell suspension was adjusted based on the test results to obtain a cerebrospinal fluid-derived cell suspension.
[0072] In step S3, cell mass preparation and matrix gel reconstitution include quantitative preparation of cerebrospinal fluid-derived cells and dilution of matrix gel for reconstitution. Based on the cell counting results of the cerebrospinal fluid-derived cell suspension obtained in S2, the cell quantity corresponding to a single mature choroid plexus organoid is prepared. Then, the matrix gel is diluted using co-culture basal medium, and the quantitatively prepared cerebrospinal fluid-derived cells are resuspended to form a cell-matrix gel mixed suspension.
[0073] Specifically, cell quantity is configured based on cell counting results of cerebrospinal fluid-derived cell suspensions to obtain a quantitative amount of cerebrospinal fluid-derived cells corresponding to a single mature choroid plexus organoid.
[0074] Each mature choroid plexus organoid corresponds to 20,000 cerebrospinal fluid-derived cells. The required volume of cell suspension is determined based on the viable cell concentration in the cerebrospinal fluid-derived cell suspension formed in S2, and the volume of cell suspension taken is determined according to... Calculate, where, This refers to the volume of the cerebrospinal fluid source cell suspension that needs to be collected. The number of cerebrospinal fluid-derived cells corresponding to a single mature choroid plexus organoid was taken as 20,000. The concentration of live cells in a cerebrospinal fluid-derived cell suspension; when When expressed in units / μL, The unit is μL.
[0075] Take the calculated volume of cerebrospinal fluid-derived cell suspension, centrifuge to collect the cells and remove excess liquid to obtain a quantitative cell precipitate containing 20,000 cerebrospinal fluid-derived cells.
[0076] Furthermore, based on a quantitative amount of cerebrospinal fluid-derived cells, a diluted matrix gel was prepared to form a cell-matrix mixed suspension.
[0077] The co-culture basal medium used was choroidal maturation medium, which was composed of DMEM / F12 and Neurobasal medium in a 1:1 volume ratio, and contained N2 additive, vitamin A-containing B27 additive, insulin, 2-mercaptoethanol, GlutaMAX, MEM non-essential amino acids, and penicillin-streptomycin mixture.
[0078] The matrix gel was mixed with the co-culture basal medium at a volume ratio of 1:5 to form a diluted matrix gel. The matrix gel dilution and cell recombination process was maintained at 2-8℃ to keep the matrix gel in a liquid state.
[0079] A quantitative cell pellet containing 20,000 cerebrospinal fluid-derived cells was resuspended in a diluted matrix gel, dispersing the cerebrospinal fluid-derived cells in the diluted matrix gel. The final mixing volume corresponding to a single mature choroid plexus organoid was adjusted to 5-10 μL to form a cell matrix gel mixed suspension.
[0080] The resulting cell matrix gel mixture suspension was kept at 2-8℃ to maintain the liquid state of the matrix gel and was directly used as the input material for S4 local implantation treatment.
[0081] In step S4, the local implantation process includes micropore formation and the introduction of a cell-matrix mixture suspension, followed by in-situ coagulation of the matrix. Micropores leading to the superficial parenchymal region are formed on the surface of the mature choroid organoid. The liquid cell-matrix mixture suspension formed in S3 enters the superficial parenchymal region through the micropores, and then the matrix is coagulated in-situ in the introduction area by heating. This transforms the spatial state of the cerebrospinal fluid-derived cells from the outside of the organoid to a fixed state within the local tissue region of the organoid.
[0082] Specifically, micropores are formed in mature choroid organoids and a mixed suspension of cell matrix gel is introduced to form organoid intermediates that can be implanted locally.
[0083] The single mature choroidal organoid formed in S1 was transferred to a sterile handling container, excess culture medium around the organoid was removed, and the surface of the organoid was kept moist.
[0084] Using a 30-32 G sterile fine needle, micropores are formed on the outer surface of mature choroid organoids towards the superficial parenchyma, with the needle insertion depth controlled at 100-300 μm. After micropore formation, 5-10 μL of a cytosolic matrix gel mixture, prepared as S3 and kept in a liquid state, is slowly introduced into the superficial parenchyma of the mature choroid organoids through the micropores, with the injection time controlled at 30-60 s.
[0085] After the mixed suspension is introduced, hold it for 1-3 minutes, then remove the injection device, so that the cell matrix gel mixed suspension remains in the surface solid area near the micropores, forming an organoid intermediate that has been locally implanted.
[0086] Furthermore, the matrix collagen is coagulated in situ based on the organoid intermediate that has been locally implanted to form an organoid complex.
[0087] The organoid intermediate was placed at 37°C and 5% CO2 for 30 min to allow the matrix gel introduced into the superficial parenchyma to change from a liquid to a solidified state. After the matrix gel solidified in situ, it spatially confined the cerebrospinal fluid-derived cells distributed in the matrix gel suspension, keeping the cerebrospinal fluid-derived cells within the local tissue region of the mature choroid organoid.
[0088] After in-situ solidification, preheated co-culture basal medium at 37°C was slowly added to the culture vessel, avoiding the local implantation area to prevent direct impact of the liquid flow on the solidification area. After the medium was added, organoid complexes were obtained and directly used as three-dimensional culture entities for S5 staged co-culture.
[0089] In step S5, the phased co-culture includes cerebrospinal fluid supernatant remixing, static culture, and orbital shaker culture. The cerebrospinal fluid supernatant obtained from the same sterile cerebrospinal fluid sample in S2 is added back to the culture system containing the organoid complex formed in S4, so that the liquid phase components of cerebrospinal fluid and the cerebrospinal fluid-derived cells that have been locally fixed in mature choroid plexus organoids are reintroduced into the same culture environment; the organoid complex is first subjected to 24 hours of static culture, and then transferred to a 70 rpm orbital shaker for continuous culture, with the culture medium being updated according to the set stages, and co-cultured until day 9 to form a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
[0090] Specifically, the cerebrospinal fluid supernatant was reconstituted based on the co-culture basal medium to form an initial co-culture system.
[0091] Take the cerebrospinal fluid supernatant obtained in S2 and the co-culture basal medium described in S3, mix the cerebrospinal fluid supernatant and the co-culture basal medium at a volume ratio of 1:5 to form a co-culture medium containing cerebrospinal fluid supernatant, and preheat it to 37°C.
[0092] The co-culture medium containing cerebrospinal fluid supernatant was slowly added to the culture well containing the organoid complex formed in S4, thus placing the organoid complex in a liquid culture environment. The co-culture time was calculated from the moment the co-culture medium containing cerebrospinal fluid supernatant was added.
[0093] During co-culture days 0-3, a co-culture medium containing cerebrospinal fluid (CSF) supernatant was used, maintaining a 1:5 volume ratio of CSF supernatant to the co-culture basal medium. If the culture medium was replaced during this time period, the newly added medium maintained the same volume ratio. After day 3, CSF supernatant was no longer added, and co-culture continued using a co-culture basal medium without CSF supernatant.
[0094] Furthermore, static culture is carried out based on the initial co-culture system to form a static co-culture system.
[0095] The initial co-culture system was placed at 37°C and 5% CO2 and incubated statically for 24 h. The culture container was kept horizontal and no orbital oscillation was applied, so that the organoid complex formed by S4 could maintain its initial co-culture state in a liquid environment containing cerebrospinal fluid supernatant.
[0096] After 24 hours of static culture, without replacing the organoid complex, the culture container is directly transferred to the track-shaking culture stage, forming a continuous state transition from static culture to track-shaking culture.
[0097] Furthermore, a co-culture model of lung cancer meningeal metastases and choroid plexus organoids was formed by using a static co-culture system and orbital shaker culture.
[0098] After 24 hours of static incubation, the culture containers were placed on a track shaker and continuously incubated at 37°C and 5% CO2 at 70 rpm. The total co-culture time was calculated from the addition of the co-culture medium containing cerebrospinal fluid supernatant at S5-1, and the total co-culture time was 9 days.
[0099] Throughout the co-culture period, the culture medium is replaced every 2-3 days, removing 50%-80% of the total volume each time and adding an equal volume of fresh culture medium preheated to 37°C. When replacing the culture medium on days 0-3 of co-culture, a co-culture medium with a cerebrospinal fluid supernatant to basal co-culture medium volume ratio of 1:5 is added; after day 3 of co-culture, basal co-culture medium without cerebrospinal fluid supernatant is added. During the culture medium replacement process, the organoid complex is preserved, and direct impact of fluid flow on the local implantation area is avoided.
[0100] The culture was continued until day 9, then the orbital shaker culture was terminated, and the resulting three-dimensional cultured entities were collected to obtain a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
[0101] The KnockOut serum substitute used in the following examples and comparative examples is a cell culture-grade serum substitute suitable for human pluripotent stem cell culture and can be purchased from Thermo Fisher Scientific; the basic fibroblast growth factor used is recombinant human FGF-2 / bFGF protein with a molecular weight of approximately 17.2 kDa and 154 amino acid residues, suitable for stem cell culture and can be purchased from Thermo Fisher Scientific; the ROCK inhibitor Y-27632 used is Y-27632 dihydrochloride, a cell experiment reagent with a purity of not less than 98%, and can be purchased from Tocris Bioscience; the N2 additive used is a 100× liquid cell culture additive and can be purchased from Thermo Fisher Scientific; the vitamin A-free B27 additive used is a 50× serum-free cell culture additive and can be purchased from Thermo Fisher Scientific; the vitamin A-containing B27 additive used is a 50× standard serum-free B27 additive and can be purchased from Thermo Fisher Scientific. Fisher Scientific; the matrix gel used can be a coagulated basement membrane matrix suitable for three-dimensional organoid culture, which can be purchased from Corning; the CHIR99021 used can be CHIR99021 with a purity of not less than 98%, which can be purchased from Tocris Bioscience; the BMP4 used can be a biologically active recombinant human BMP4 protein, which can be purchased from Thermo Fisher Scientific.
[0102] The sterile cerebrospinal fluid from lung cancer patients with meningeal metastases used in the following examples and comparative examples were clinical samples from patients. The cerebrospinal fluid supernatant and cell precipitate were obtained by low-temperature centrifugation, and the cell precipitate was further used to obtain a cerebrospinal fluid-derived cell suspension.
[0103] Example 1:
[0104] This embodiment provides a method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids, with two model biological replicates set up in each group, including the following steps:
[0105] S1: Directed construction of choroidal organoids from human pluripotent stem cells to form mature choroidal organoids.
[0106] Human pluripotent stem cells in a stable proliferative state were collected, processed with cell digestion solution to form a single-cell suspension, and cell counting was performed after digestion was terminated. 3000 human pluripotent stem cells were seeded into single wells of a 96-well round-bottom ultra-low adsorption culture plate, and 180 μL of organoid formation culture medium was added to each well. The plates were cultured at 37°C and 5% CO2.
[0107] The organoid formation medium was based on DMEM / F12, supplemented with 18% KnockOut serum substitute, 2.5% fetal bovine serum, 1% GlutaMAX, 1% MEM non-essential amino acids, 0.10 mM 2-mercaptoethanol, and 4 ng / mL basic fibroblast growth factor. During days 0-3, 20 μM of the ROCK inhibitor Y-27632 was added. After day 3, the medium was replaced with organoid formation medium without Y-27632, and culture continued until day 5 to obtain initial organoids.
[0108] On day 5 of culture, the organoid formation medium was replaced with neural induction medium. The neural induction medium was based on DMEM / F12, with the addition of 1% N2 additive, 1% GlutaMAX, 1% MEM non-essential amino acids, and 1 μg / mL heparin. No serum or serum substitutes were added. After culturing at 37°C and 5% CO2 for day 7, neurally induced organoids with a continuous translucent tissue region on the periphery were obtained.
[0109] Neurally induced organoids were harvested, and residual culture medium was removed from their surfaces. Individual organoids were embedded in 25 μL of cryogenic liquid matrix gel and incubated at 37°C for 20 min to allow the matrix gel to solidify. The embedded organoids were then transferred to ultra-low adsorption plates and cultured in amplification medium until day 10. The amplification medium consisted of a 1:1 volume ratio of DMEM / F12 and Neurobasal medium as the basal medium, supplemented with 0.5% N2 additive, 2% vitamin A-free B27 additive, 2.5 μg / mL insulin, 50 μM 2-mercaptoethanol, 1% GlutaMAX, 0.5% MEM non-essential amino acids, and 1% penicillin-streptomycin mixture. After 10 days of culture, amplified organoids with budding structures on their surface were obtained.
[0110] The amplification medium was replaced with choroid plexus differentiation medium. The choroid plexus differentiation medium was a basal culture medium composed of DMEM / F12 and Neurobasal medium at a 1:1 volume ratio, with the addition of 0.5% N2 additive, 2% vitamin A-containing B27 additive, 2.5 μg / mL insulin, 50 μM 2-mercaptoethanol, 1% GlutaMAX, 0.5% MEM non-essential amino acids, 1% penicillin-streptomycin mixture, 3 μM CHIR99021, and 20 ng / mL BMP4. The medium was replaced with fresh choroid plexus differentiation medium on day 13, and cultured until day 15.
[0111] On day 15, the choroid plexus differentiation medium was replaced with choroid plexus maturation medium. The choroid plexus maturation medium used the same basal medium and nutrient supplements as the choroid plexus differentiation medium, but without CHIR99021 and BMP4. The culture was carried out in a track-shaking incubator at 37°C and 5% CO2 at 65 rpm, with the medium replaced with fresh choroid plexus maturation medium every 3 days, until day 30, yielding mature choroid plexus organoids with dense tissue regions and peripheral sac-like structures.
[0112] Representative samples were taken from the same batch of mature choroid plexus organoids for AQP1, MAP2, and DAPI immunofluorescence staining, as well as HE staining, to confirm the tissue state of the choroid plexus organoids before co-culture. The AQP1 / MAP2 / DAPI immunofluorescence detection results are as follows: Figure 2 As shown, the HE staining results are as follows: Figure 3 As shown. Another representative sample was used for Western blot detection of cerebrospinal fluid chaperone proteins; the results are shown below. Figure 4 As shown. The remaining mature choroidal organelles proceed to step S4.
[0113] S2: Component separation and cell pretreatment of sterile cerebrospinal fluid from patients with lung cancer meningeal metastases were performed to obtain cerebrospinal fluid supernatant and cerebrospinal fluid-derived cell suspension.
[0114] Sterile cerebrospinal fluid was transferred to sterile centrifuge tubes and centrifuged at 1000 r / min for 10 min at 4°C. After centrifugation, the supernatant was collected without disturbing the cell pellet, while the cell pellet at the bottom of the tube was retained. The cerebrospinal fluid supernatant was stored at 4°C and used within 24 h for the preparation of subsequent co-culture media.
[0115] Add 4 times the volume of erythrocyte lysis buffer to the cell pellet, mix gently, and incubate at 4°C for 2 min. Terminate and dilute the erythrocyte lysis buffer with PBS, centrifuge at 400×g for 8 min, and discard the supernatant. Resuspend the cell pellet in PBS and wash once more. Then, form a cell suspension with PBS and filter through a 70 μm cell sieve. Collect the filtrate, perform cell counting and viability testing, and adjust the cell concentration based on the counting results to obtain a cerebrospinal fluid-derived cell suspension.
[0116] S3: Based on cerebrospinal fluid-derived cell suspensions, cell volume is prepared and matrix gel is compounded to form a cell-matrix mixed suspension.
[0117] Based on the live cell concentration of the cerebrospinal fluid-derived cell suspension obtained in S2, according to Calculate the volume of cell suspension required for a single mature choroid plexus organoid. Among these, Take 20,000. This refers to the concentration of live cells in a cerebrospinal fluid-derived cell suspension. The volume of the corresponding cell suspension to be taken.
[0118] Take a cell suspension containing 20,000 cerebrospinal fluid-derived cells according to the calculated volume, centrifuge at 400×g for 5 min, remove excess liquid and retain cell precipitate.
[0119] Choroid plexus maturation medium was used as the basal medium for co-culture. The matrix gel was mixed with the basal medium at a 1:5 volume ratio to form a diluted matrix gel. The matrix gel dilution and cell recombination processes were performed at 4°C. The cell pellet containing 20,000 cerebrospinal fluid-derived cells was resuspended in the diluted matrix gel, and the total volume of the matrix gel suspension corresponding to a single mature choroid organoid was adjusted to 8 μL, and maintained at 4°C.
[0120] S4: Local implantation of mature choroid organoids is performed by introducing a cell matrix gel suspension into the mature choroid organoids and coagulating it in situ to form an organoid complex.
[0121] A single mature choroidal organoid was transferred to a sterile handling container, excess culture medium around the organoid was removed, and the organoid surface was kept moist.
[0122] A 31G sterile fine needle was used to create micropores on the outer surface of mature choroid organoids, extending 200 μm into the superficial parenchyma. 8 μL of the S3-formed cell matrix gel suspension was slowly introduced into the superficial parenchyma through the micropores over 45 seconds. After introduction, the suspension was held for 2 minutes before being slowly removed.
[0123] The organoids that had been locally implanted were placed at 37°C and 5% CO2 for 30 minutes to allow the matrix collagen in the implantation area to solidify. After solidification, co-culture basal medium preheated to 37°C was slowly added, avoiding the local implantation area, to obtain organoid complexes.
[0124] S5: Organoid complexes were co-cultured in stages using cerebrospinal fluid supernatant to obtain a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
[0125] The cerebrospinal fluid supernatant obtained from S2 was mixed with the co-culture basal medium at a volume ratio of 1:5 to form a co-culture medium, which was then preheated to 37°C. The co-culture medium was slowly added to the culture well containing the organoid complex, and the co-culture time was calculated from the time the co-culture medium was added.
[0126] The initial co-culture system was statically incubated at 37℃ and 5% CO2 for 24 h without any orbital oscillation. After static incubation, the culture container was transferred to an orbital shaker and incubated at 37℃ and 5% CO2 at 70 rpm.
[0127] For days 0-3 of co-culture, a co-culture medium with a volume ratio of cerebrospinal fluid supernatant to co-culture basal medium of 1:5 was used. After day 3, co-culture continued using co-culture basal medium without cerebrospinal fluid supernatant. The culture medium was replaced on days 3 and 6, with 60% of the total culture medium volume removed each time and an equal volume of fresh culture medium preheated to 37°C added. The culture medium added on days 3 and 6 was co-culture basal medium without cerebrospinal fluid supernatant.
[0128] The culture was continued until day 9, at which point the orbital shaker culture was terminated and the three-dimensional cultured entities were collected to obtain a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
[0129] Each biological replicate independently completed the above model construction process. After collecting the models on day 9 of co-culture, CK7, TTF1 and DAPI staining were performed using the same fixation, sectioning and immunofluorescence staining conditions, and the total number of cells, the number of CK7 positive cells and the number of TTF1 positive cells required for subsequent evaluation were obtained under the same microscopic imaging and cell statistics rules.
[0130] Comparative Example 1:
[0131] This comparative example uses a drop-addition co-preparation method, with two model organism replicates in each group. The difference between this comparative example and Example 1 lies in the different binding mode between the cerebrospinal fluid-derived cells and the mature choroid plexus organoids in step S4.
[0132] Steps S1 to S3 are performed according to Example 1 to form a mature choroid plexus organoid and an 8 μL cell matrix gel mixed suspension corresponding to a single mature choroid plexus organoid. The cell matrix gel mixed suspension contains 20,000 cerebrospinal fluid-derived cells, and the volume ratio of matrix gel to co-culture basal medium is 1:5.
[0133] In step S4, a single mature choroid organoid is placed in a sterile culture container, excess culture medium is removed and the surface of the organoid is kept moist, and 8 μL of a cell matrix gel suspension is directly dropped onto the outer surface of the mature choroid organoid so that the cell matrix gel suspension comes into contact with the surface of the organoid.
[0134] After the addition was completed, the mature choroidal organoids were placed at 37°C and 5% CO2 for 30 minutes to allow the matrix gel added to the surface of the organoids to solidify. After solidification, pre-warmed co-culture basal medium at 37°C was slowly added to form the dropwise co-prepared organoid culture system.
[0135] Step S5 was performed according to Example 1. The supernatant of cerebrospinal fluid obtained from the same cerebrospinal fluid sample was mixed with the co-culture basal medium at a volume ratio of 1:5 to prepare the co-culture medium. After static incubation for 24 h, the medium was cultured on a track shaker at 70 rpm for a total co-culture time of 9 days. The supernatant of cerebrospinal fluid was added for the first 3 days of co-culture. After the 3rd day, the co-culture basal medium without the supernatant of cerebrospinal fluid was used for continued culture. 60% of the culture medium was replaced on the 3rd and 6th days, respectively.
[0136] On day 9 of co-culture, the three-dimensional cultured entities formed by adding the co-prepared solution were collected and subsequently detected using the same fixation, sectioning, CK7 / TTF1 / DAPI immunofluorescence staining, microscopic imaging, and cell statistics conditions as in Example 1.
[0137] Comparative Example 2:
[0138] This comparative study used the chip co-matching method, with two model organism replicates in each group.
[0139] Mature choroid organoids were constructed according to the culture conditions in step S1 of Example 1, and sterile cerebrospinal fluid from the same batch of lung cancer meningeal metastasis patients was subjected to low-temperature centrifugation, red blood cell lysis, PBS washing, 70 μm cell sieve filtration, cell counting, and viability detection according to the processing conditions in step S2, to obtain cerebrospinal fluid supernatant and cerebrospinal fluid-derived cell suspension, respectively.
[0140] A co-culture system for cerebrospinal fluid (CSF)-derived cells and mature choroid plexus organoids was established using an existing microfluidic chip co-location pathway. Mature choroid plexus organoids were placed in the chip's culture region designated to support choroid plexus-related culture subjects. Based on the count results of the CSF-derived cell suspension, 20,000 CSF-derived cells were prepared and added to the cell culture region within the chip corresponding to the mature choroid plexus organoids. The spatial co-culture relationship between the CSF-derived cells and the mature choroid plexus organoids was maintained by the chip's internal culture region and flow path.
[0141] The basal culture medium used for chip co-culture was the same as that used in Example 1. During days 0-3 of co-culture, cerebrospinal fluid supernatant was mixed with the basal culture medium at a 1:5 volume ratio and added to the chip culture system. After day 3, co-culture continued using a basal culture medium without cerebrospinal fluid supernatant. The chip maintained the exchange of culture media between the cultured objects according to the existing co-combination device's flow path structure and operating conditions. The internal geometry and fluid operation parameters of the chip remained at the predetermined settings of the chip co-combination device used.
[0142] The culture time was calculated from the addition of co-culture medium containing cerebrospinal fluid supernatant and continued for 9 days. During the culture period, the culture environment was maintained at 37°C and 5% CO2. The amount of cerebrospinal fluid-derived cells input, the proportion of cerebrospinal fluid supernatant added, the stage of cerebrospinal fluid supernatant addition, and the total co-culture time were consistent with those in Example 1.
[0143] On day 9 of co-culture, the cultured objects in the chip co-culture system were collected and subsequently detected using the same fixation, sectioning, CK7 / TTF1 / DAPI immunofluorescence staining, microscopic imaging, and cell statistics conditions as in Example 1.
[0144] Experimental Example 1:
[0145] This experiment uses the co-culture subjects formed in Example 1, Comparative Example 1, and Comparative Example 2 as experimental subjects. Specifically, Example 1 uses a complete co-culture model of lung cancer meningeal metastases and choroid plexus organoids; Comparative Example 1 uses a drop-addition co-mixing method; and Comparative Example 2 uses a chip co-mixing method.
[0146] Two replicas of the model organisms were set up in each group. Example 1 and Comparative Example 1 used the same mature choroid plexus organoids, cerebrospinal fluid-derived cell input volume, matrix gel dilution ratio, cerebrospinal fluid supernatant addition ratio, culture medium composition, culture time, and culture environment. Comparative Example 2 maintained the same cerebrospinal fluid-derived cell input volume, total co-culture time, and immunofluorescence detection time points as Example 1.
[0147] Before mature choroidal organoids were co-cultured, representative samples were selected from the same batch of organoids for tissue characterization. HE staining was used to observe tissue morphology, and AQP1, MAP2 and DAPI were used for immunofluorescence staining. AQP1 was used as a choroidal plexus cell marker, and MAP2 was used as a preplate cell marker.
[0148] After the three groups completed 9 days of co-culture, the cultured subjects were collected separately, fixed, sectioned, and subjected to CK7, TTF1 and DAPI immunofluorescence staining under the same conditions, and detected using the same microscopic imaging conditions and cell statistical rules.
[0149] This experimental example performs the following tests:
[0150] Test 1: Detection of the proportion of CK7 positive cells.
[0151] The culture subjects obtained after co-culturing for 9 days in Examples 1, 1, and 2 were used as test subjects. All samples were fixed and sectioned using the same method, and then subjected to CK7, TTF1, and DAPI immunofluorescence staining. Images of the statistical regions were acquired under the same imaging conditions using fluorescence microscopy. The total number of cells within the statistical regions was determined by DAPI staining, and the number of CK7-positive cells within the same statistical region was also counted.
[0152] The proportion of CK7 positive cells according to Calculation. Among them, The percentage of CK7-positive cells, in % To count the number of CK7-positive cells in the region; The total number of cells determined by DAPI within the same statistical region.
[0153] The proportion of CK7-positive cells was calculated for each model biological replicate, and the mean and sample standard deviation of the results from the two model biological replicates in the same group were calculated. Under the same staining, microscopic imaging, and statistical conditions, the proportion of CK7-positive cells was used to characterize the detection and maintenance status of CK7-positive cells in the co-culture model. A higher value indicates a higher proportion of CK7-positive cells in the corresponding statistical region.
[0154] Test 2: Detection of the proportion of TTF1 positive cells.
[0155] Using the same sample pretreatment, immunofluorescence staining, and microscopic imaging conditions as Test 1, the total number of cells in the statistical region was determined by DAPI, and the number of TTF1 positive cells in the same statistical region was also counted.
[0156] The proportion of TTF1 positive cells according to Calculation. Among them, The percentage of TTF1-positive cells, expressed as % To count the number of TTF1-positive cells in the region; The total number of cells determined by DAPI within the same statistical region.
[0157] The proportion of TTF1-positive cells was calculated for each model biological replicate, and the mean and sample standard deviation of the results from the two model biological replicates in the same group were calculated. Under the same test conditions, the proportion of TTF1-positive cells was used to characterize the detection and maintenance status of TTF1-positive lung-derived cells in the model. CK7 and TTF1 reflect the status of lung cancer-derived cells after co-culture from different biomarker dimensions; therefore, both indicators were used to jointly evaluate models obtained from different co-culture pathways.
[0158] The representative CK7 / TTF1 / DAPI immunofluorescence detection results of the culture subjects obtained on day 9 of co-culture in Example 1, Comparative Example 1, and Comparative Example 2 are as follows: Figure 5 , Figure 6 and Figure 7 As shown.
[0159] The original detection results of the three groups of two model biological replicates are shown in the table below.
[0160] Table 1
[0161]
[0162] The descriptive statistics obtained from the biological replication calculations of the two models are shown in the table below.
[0163] Table 2
[0164]
[0165] Example 1, Comparative Example 1, and Comparative Example 2 employed different co-culture space construction methods. Therefore, the differences in the experimental results of the three groups were mainly related to the initial spatial position of the cerebrospinal fluid-derived cells after entering the culture system, the contact mode between the cells and the choroid plexus tissue, and the maintenance of this spatial relationship during subsequent culture. In Example 1, the average proportion of CK7-positive cells was 37.27%, and the average proportion of TTF1-positive cells was 23.54%; the corresponding averages in Comparative Example 1 were 22.71% and 8.27%, respectively; and the corresponding averages in Comparative Example 2 were 16.50% and 10.24%, respectively.
[0166] The main difference between Example 1 and Comparative Example 1 lies in the initial spatial position of the cell-MSG suspension relative to the mature choroid plexus organoid. In Example 1, micropores were formed on the surface of the mature choroid plexus organoid, and the cell-MSG suspension was directly introduced into the surface parenchyma region; in Comparative Example 1, the same cell-MSG suspension was dropped onto the outer surface of the organoid. In Comparative Example 1, the cerebrospinal fluid-derived cells were primarily located on the outer surface of the organoid at the start of culture, and the contact between the cells and the organoid tissue depended on surface adhesion and the local contact relationships formed during subsequent culture. In Example 1, the cerebrospinal fluid-derived cells were introduced into the surface parenchyma region of the organoid before the start of continuous co-culture; therefore, the initial position of the cells directly overlapped with the three-dimensional choroid plexus tissue, reducing the spatial process required for the cells to gradually approach or enter the tissue region from the outside of the organoid.
[0167] The in-situ coagulation of matrix gel in Example 1 further enhanced the aforementioned spatial differences. When the cell-matrix mixture suspension entered the superficial parenchymal region, the matrix gel was in a flowable state; after in-situ coagulation at 37°C, the matrix gel formed a local gel region at the insertion site, spatially restricting the cerebrospinal fluid-derived cells within it. Thus, microporous implantation is responsible for transferring the position of cerebrospinal fluid-derived cells from the organoid exterior to the superficial parenchymal region, while in-situ coagulation of the matrix gel transforms the established positional relationship from a temporary insertion state to a relatively stable local fixation state.
[0168] During the subsequent 9 days of co-culture, the local immobilization state reduced the likelihood of cerebrospinal fluid-derived cells detaching from the local organoid region due to culture medium movement, medium renewal, and orbital shaker culture. This ensured that more cerebrospinal fluid-derived cells remained within the three-dimensional tissue microenvironment of the mature choroid plexus organoid. In contrast, the cells in Comparative Example 1 were cultured primarily from the outer surface of the organoid. Even when the matrix gel solidified on the surface, it did not form the same internal spatial confinement relationship as the surface solid region of the organoid. As culture medium exchange and orbital shaker culture continued, the cells located on the outside or surface were more directly affected by the liquid environment, and the conditions under which they maintained continuous local contact with the organoid tissue differed from those in Example 1.
[0169] The inter-group differences in the proportion of TTF1-positive cells were particularly pronounced. The average proportion in Example 1 was 23.54%, while the average in Comparative Example 1 was 8.27%. TTF1 is used to characterize the detection and maintenance status of TTF1-positive lung-derived cells in the model. Therefore, when cerebrospinal fluid-derived cells are maintained in the local tissue region of the choroid plexus organoid for a longer period through local implantation and in situ fixation, the proportion of TTF1-positive lung-derived cells detectable at the co-culture endpoint is correspondingly higher. The proportion of CK7-positive cells also showed the same overall trend, with an average of 37.27% in Example 1 and an average of 22.71% in Comparative Example 1.
[0170] The difference between Example 1 and Comparative Example 2 stems from a more holistic change in spatial organization. Comparative Example 2 employs a chip-based co-location approach, avoiding direct implantation of cerebrospinal fluid-derived cells into mature choroid plexus organoids. Instead, it relies on pre-defined culture areas and flow paths within the chip to maintain the spatial relationships between different culture subjects. This method allows cerebrospinal fluid-derived cells and choroid plexus-related culture subjects to be within the same chip culture system, but their spatial relationships are still organized and constrained by the chip structure. The cells and mature choroid plexus organoids do not exhibit the intra-tissue binding state seen in Example 1.
[0171] Example 1 directly used mature choroidal organoids as a three-dimensional culture medium, allowing cerebrospinal fluid-derived cells to enter the local parenchymal region of the organoid and participate in subsequent culture. This treatment transformed the spatial environment of tumor cells from adjacent or partitioned culture within a microarray to a local coexistence state within the organoid tissue. The spatial distance between cells and choroidal plexus tissue, the local contact pattern, and the exchange pathway between the culture medium and the tissue all changed accordingly. At the same co-culture endpoint, the average proportion of CK7-positive cells in Example 1 was 37.27%, higher than the 16.50% in Comparative Example 2; the average proportion of TTF1-positive cells was 23.54%, higher than the 10.24% in Comparative Example 2.
[0172] Meanwhile, Example 1 established a direct spatial relationship between cells and tissues through local implantation within mature choroidal organoids and matrix gel fixation, while Comparative Example 2 maintained the spatial relationship between cultured subjects through microarray culture regions. These different spatial organization mechanisms further influenced the local culture state of cerebrospinal fluid-derived cells throughout the entire co-culture period.
[0173] In Example 1, the reconstitution and staged culture of cerebrospinal fluid supernatant were performed after the aforementioned local spatial state had been established. After the cerebrospinal fluid-derived cells were separated from the cerebrospinal fluid, the cerebrospinal fluid supernatant was independently retained as a liquid component of the same sample. After the organoid complex was formed, the cerebrospinal fluid supernatant was added to the co-culture system at a volume ratio of 1:5, so that the separated cell components and liquid components were once again placed in the same culture environment. At this time, the cerebrospinal fluid supernatant did not act on the freely suspended cerebrospinal fluid-derived cells, but rather on the cells that had been locally implanted and fixed in the mature choroid plexus organoids. Therefore, the restoration of the liquid environment was based on the already established spatial relationship of cell tissue.
[0174] After adding cerebrospinal fluid supernatant, the cells were incubated statically for 24 hours before being transferred to a 70 rpm orbital shaker, maintaining continuity with the aforementioned spatial construction process. Although the cell-matrix mixture suspension had already solidified in situ, applying continuous orbital oscillations immediately upon the local implantation area entering the liquid co-culture environment would subject the organoid complex to a dynamic liquid environment. An initial static culture phase was established to allow the in-situ fixed cells, solidified matrix gel, and local organoid tissue to co-maintain in a relatively static culture environment. Once this state was achieved, the cells were transferred to the orbital shaker, allowing the culture system to enter a continuous dynamic culture phase.
[0175] Based on the preferred embodiments of the present invention described above, those skilled in the art can make various changes and modifications without departing from the inventive concept. The technical scope of this invention is not limited to the contents of the specification, but must be determined according to the scope of the claims.
Claims
1. A method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids, characterized in that, Includes the following steps: S1: Directed construction of choroidal organoids from human pluripotent stem cells to form mature choroidal organoids; S2: Component separation and cell pretreatment of sterile cerebrospinal fluid from patients with lung cancer meningeal metastasis to obtain cerebrospinal fluid supernatant and cerebrospinal fluid-derived cell suspension; S3: Cell volume preparation and matrix gel compounding based on cerebrospinal fluid-derived cell suspension to form a cell-matrix mixed suspension; S4: Local implantation of mature choroidal organoids is performed by introducing a cell matrix gel mixture suspension into the mature choroidal organoids and coagulating it in situ to form an organoid complex. S5: Using cerebrospinal fluid supernatant, organoid complexes were co-cultured in stages to obtain a co-culture model of lung cancer meningeal metastases and choroid plexus organoids.
2. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 1, characterized in that, Micropores leading to the superficial solid region are formed on the surface of mature choroidal organoids. A liquid cell matrix gel suspension is introduced into the superficial solid region through the micropores, and the matrix gel is solidified in situ in the introduced region by heating, so that the cerebrospinal fluid-derived cells are fixed in the local tissue region of the mature choroidal organoid.
3. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 2, characterized in that, Each mature choroid organoid is configured with 20,000 cerebrospinal fluid-derived cells. The matrix gel and co-culture basal medium are mixed at a volume ratio of 1:5 to form a diluted matrix gel. The cerebrospinal fluid-derived cells are resuspended in the diluted matrix gel. The final mixing volume of the matrix gel suspension corresponding to each mature choroid organoid is adjusted to 5-10 μL. The matrix gel dilution and cell recombining process is maintained at 2-8℃.
4. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 2, characterized in that, Using a 30-32 G sterile fine needle, micropores are formed from the outer surface of mature choroid organoids to the surface parenchymal region, with a needle depth of 100-300 μm. The cell matrix gel suspension is introduced into the surface parenchymal region through the micropores for 30-60 s. After the introduction is completed, it is held for 1-3 min before the injection device is removed. Subsequently, it is kept at 37℃ and 5% CO2 for 30 min to allow the matrix gel to solidify in situ.
5. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 2, characterized in that, The cerebrospinal fluid supernatant and the cerebrospinal fluid-derived cells are derived from the same sterile cerebrospinal fluid sample. After the organoid complex is formed, the cerebrospinal fluid supernatant is mixed with the co-culture basal medium at a volume ratio of 1:5 to form a co-culture medium containing the cerebrospinal fluid supernatant, and then added to the culture system containing the organoid complex, so that the cerebrospinal fluid supernatant and the cerebrospinal fluid-derived cells fixed in the local tissue area of the mature choroid organoid are once again in the same culture environment.
6. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 5, characterized in that, The co-culture medium containing cerebrospinal fluid supernatant was used for co-culture from day 0 to day 3. After day 3, the co-culture medium without cerebrospinal fluid supernatant was used. The organoid complex was first statically cultured at 37°C and 5% CO2 for 24 h, and then transferred to a track shaker and continuously cultured at 37°C and 5% CO2 at 70 rpm for a total co-culture time of 9 days.
7. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 1, characterized in that, The sterile cerebrospinal fluid was centrifuged at 1000 r / min for 10 min at 4°C to obtain cerebrospinal fluid supernatant and cell pellet. The cell pellet was subjected to red blood cell lysis, PBS washing, filtration through a 70 μm cell sieve, cell counting, and viability testing to obtain the cerebrospinal fluid-derived cell suspension.
8. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 1, characterized in that, The choroid plexus organoid targeted construction includes single-cell culture and aggregation, neural induction culture, matrix gel embedding and three-dimensional expansion culture, and choroid plexus differentiation and maturation culture. Specifically, initial organoids are formed on days 0-5, neural induction organoids are formed on days 5-7, expanded organoids are formed on days 7-10, choroid plexus differentiation culture is performed on days 10-15, and choroid plexus maturation culture is performed on days 15-30.
9. The method for constructing a co-culture model of lung cancer meningeal metastases and choroid plexus organoids according to claim 8, characterized in that, From day 10 to 15, choroid plexus differentiation culture was performed using choroid plexus differentiation medium containing 2-4 μM CHIR99021 and 15-25 ng / mL BMP4. After day 15, choroid plexus maturation medium without CHIR99021 and BMP4 was used, and the culture was carried out in an orbital shaker at 37℃ and 5% CO2 at 55-75 rpm. Fresh choroid plexus maturation medium was replaced every 3-4 days, and the culture was continued until day 30.
10. A co-culture model of lung cancer meningeal metastases and choroid plexus organoids, characterized in that, The co-culture model of lung cancer meningeal metastases and choroid plexus organoids is obtained by the construction method according to any one of claims 1 to 9.
